People who are taller are at greater risk of developing cancer. The World Cancer Research Fund reports there is strong evidence taller people have a higher chance of of developing cancer of the:

• pancreas
• large bowel
• uterus (endometrium)
• ovary
• prostate
• kidney
• skin (melanoma) and
• breast (pre- and post-menopausal).

But why? Here’s what we know, don’t know and suspect.

A well established pattern

The UK Million Women Study found that for 15 of the 17 cancers they investigated, the taller you are the more likely you are to have them.

It found that overall, each ten-centimetre increase in height increased the risk of developing a cancer by about 16%. A similar increase has been found in men.

Let’s put that in perspective. If about 45 in every 10,000 women of average height (about 165 centimetres) develop cancer each year, then about 52 in each 10,000 women who are 175 centimetres tall would get cancer. That’s only an extra seven cancers.

So, it’s actually a pretty small increase in risk.

Another study found 22 of 23 cancers occurred more commonly in taller than in shorter people.

Why?

The relationship between height and cancer risk occurs across ethnicities and income levels, as well as in studies that have looked at genes that predict height.

These results suggest there is a biological reason for the link between cancer and height.

While it is not completely clear why, there are a couple of strong theories.

The first is linked to the fact a taller person will have more cells. For example, a tall person probably has a longer large bowel with more cells and thus more entries in the large bowel cancer lottery than a shorter person.

Scientists think cancer develops through an accumulation of damage to genes that can occur in a cell when it divides to create new cells.

The more times a cell divides, the more likely it is that genetic damage will occur and be passed onto the new cells.

The more damage that accumulates, the more likely it is that a cancer will develop.

A person with more cells in their body will have more cell divisions and thus potentially more chance that a cancer will develop in one of them.

Some research supports the idea having more cells is the reason tall people develop cancer more and may explain to some extent why men are more likely to get cancer than women (because they are, on average, taller than women).

However, it’s not clear height is related to the size of all organs (for example, do taller women have bigger breasts or bigger ovaries?).

One study tried to assess this. It found that while organ mass explained the height-cancer relationship in eight of 15 cancers assessed, there were seven others where organ mass did not explain the relationship with height.

It is worth noting this study was quite limited by the amount of data they had on organ mass.

Another theory is that there is a common factor that makes people taller as well as increasing their cancer risk.

One possibility is a hormone called insulin-like growth factor 1 (IGF-1). This hormone helps children grow and then continues to have an important role in driving cell growth and cell division in adults.

This is an important function. Our bodies need to produce new cells when old ones are damaged or get old. Think of all the skin cells that come off when you use a good body scrub. Those cells need to be replaced so our skin doesn’t wear out.

However, we can get too much of a good thing. Some studies have found people who have higher IGF-1 levels than average have a higher risk of developing breast or prostate cancer.

But again, this has not been a consistent finding for all cancer types.

It is likely that both explanations (more cells and more IGF-1) play a role.

But more research is needed to really understand why taller people get cancer and whether this information could be used to prevent or even treat cancers.

I’m tall. What should I do?

If you are more LeBron James than Lionel Messi when it comes to height, what can you do?

Firstly, remember height only increases cancer risk by a very small amount.

Secondly, there are many things all of us can do to reduce our cancer risk, and those things have a much, much greater effect on cancer risk than height.

We can take a look at our lifestyle. Try to:

• eat a healthy diet
• exercise regularly
• maintain a healthy weight
• be careful in the sun
• limit alcohol consumption.

And, most importantly, don’t smoke!

If we all did these things we could vastly reduce the amount of cancer.

You can also take part in cancer screening programs that help pick up cancers of the breast, cervix and bowel early so they can be treated successfully.

Finally, take heart! Research also tells us that being taller might just reduce your chance of having a heart attack or stroke.

Susan Jordan, Associate Professor of Epidemiology, The University of Queensland and Karen Tuesley, Postdoctoral Research Fellow, School of Public Health, The University of Queensland

This article is republished from The Conversation under a Creative Commons license. Read the original article.

In a recent TikTok video, Australian media personality Abbie Chatfield shared she was starting a vaccine to protect against urinary tract infections (UTIs).

Huge news for the UTI girlies. I am starting a UTI vaccine tonight for the first time.

Chatfield suffers from recurrent UTIs and has turned to the Uromune vaccine, an emerging option for those seeking relief beyond antibiotics.

But Uromune is not a traditional vaccine injected to your arm. So what is it and how does it work?

First, what are UTIs?

UTIs are caused by bacteria entering the urinary system. This system includes the kidneys, bladder, ureters (thin tubes connecting the kidneys to the bladder), and the urethra (the tube through which urine leaves the body).

The most common culprit is Escherichia coli (E. coli), a type of bacteria normally found in the intestines.

While most types of E. coli are harmless in the gut, it can cause infection if it enters the urinary tract. UTIs are particularly prevalent in women due to their shorter urethras, which make it easier for bacteria to reach the bladder.

Roughly 50% of women will experience at least one UTI in their lifetime, and up to half of those will have a recurrence within six months.

The symptoms of a UTI typically include a burning sensation when you wee, frequent urges to go even when the bladder is empty, cloudy or strong-smelling urine, and pain or discomfort in the lower abdomen or back. If left untreated, a UTI can escalate into a kidney infection, which can require more intensive treatment.

While antibiotics are the go-to treatment for UTIs, the rise of antibiotic resistance and the fact many people experience frequent reinfections has sparked more interest in preventive options, including vaccines.

What is Uromune?

Uromune is a bit different to traditional vaccines that are injected into the muscle. It’s a sublingual spray, which means you spray it under your tongue. Uromune is generally used daily for three months.

It contains inactivated forms of four bacteria that are responsible for most UTIs, including E. coli. By introducing these bacteria in a controlled way, it helps your immune system learn to recognise and fight them off before they cause an infection. It can be classified as an immunotherapy.

A recent study involving 1,104 women found the Uromune vaccine was 91.7% effective at reducing recurrent UTIs after three months, with effectiveness dropping to 57.6% after 12 months.

These results suggest Uromune could provide significant (though time-limited) relief for women dealing with frequent UTIs, however peer-reviewed research remains limited.

Any side effects of Uromune are usually mild and may include dry mouth, slight stomach discomfort, and nausea. These side effects typically go away on their own and very few people stop treatment because of them. In rare cases, some people may experience an allergic reaction.

How can I access it?

In Australia, Uromune has not received full approval from the Therapeutic Goods Administration (TGA), and so it’s not something you can just go and pick up from the pharmacy.

However, Uromune can be accessed via the TGA’s Special Access Scheme or the Authorised Prescriber pathway. This means a GP or specialist can apply for approval to prescribe Uromune for patients with recurrent UTIs. Once the patient has a form from their doctor documenting this approval, they can order the vaccine directly from the manufacturer.

Uromune is not covered under the Pharmaceutical Benefits Scheme, meaning patients must cover the full cost out-of-pocket. The cost of a treatment program is around A$320.

Uromune is similarly available through special access programs in places like the United Kingdom and Europe.

Other options in the pipeline

In addition to Uromune, scientists are exploring other promising UTI vaccines.

Uro-Vaxom is an established immunomodulator, a substance that helps regulate or modify the immune system’s response to bacteria. It’s derived from E. coli proteins and has shown success in reducing UTI recurrences in several studies. Uro-Vaxom is typically prescribed as a daily oral capsule taken for 90 days.

FimCH, another vaccine in development, targets something called the adhesin protein that helps E. coli attach to urinary tract cells. FimCH is typically administered through an injection and early clinical trials have shown promising results.

Meanwhile, StroVac, which is already approved in Germany, contains inactivated strains of bacteria such as E. coli and provides protection for up to 12 months, requiring a booster dose after that. This injection works by stimulating the immune system in the bladder, offering temporary protection against recurrent infections.

These vaccines show promise, but challenges like achieving long-term immunity remain. Research is ongoing to improve these options.

No magic bullet, but there’s reason for optimism

While vaccines such as Uromune may not be an accessible or perfect solution for everyone, they offer real hope for people tired of recurring UTIs and endless rounds of antibiotics.

Although the road to long-term relief might still be a bit bumpy, it’s exciting to see innovative treatments like these giving people more options to take control of their health.

Iris Lim, Assistant Professor in Biomedical Science, Bond University

This article is republished from The Conversation under a Creative Commons license. Read the original article.